Reversibility of neuropathology in tay-sachs-related diseases

Human Molecular Genetics

Volumn 23, Issue 3, 2014, Pages 730-748

  Cachón González, María Begona ^a   Wang, Susan Z ^a   Ziegler, Robin ^b   Cheng, Seng H ^b   Cox, Timothy M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA SYNUCLEIN; BETA ACTIN; BETA N ACETYLHEXOSAMINIDASE A; BETA N ACETYLHEXOSAMINIDASE B; BETA TUBULIN; GANGLIOSIDE GM2; GLYCOCONJUGATE; MYELIN; SYNAPTOPHYSIN; UBIQUITINATED PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENE TRANSFER; HISTOLOGY; IN SITU HYBRIDIZATION; INTRACRANIAL DRUG ADMINISTRATION; MOUSE; MYELINATION; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SANDHOFF DISEASE; SURVIVAL; TAY SACHS DISEASE; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

ALPHA-SYNUCLEIN; ANIMALS; BETA-N-ACETYLHEXOSAMINIDASES; BRAIN; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; G(M2) GANGLIOSIDE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRALESIONAL; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; SANDHOFF DISEASE; TAY-SACHS DISEASE; UBIQUITIN;

EID: 84892459634     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt459     Document Type: Article

References (62)

1. Sandhoff, K., Andreae, U., and Jatzkewitz, H. (1968) Deficient hexosaminidase activity in an exceptional case of Tay-Sachs disease with additional storage of kidney globoside in visceral organs. Life Sci., 7, 283-288.
2. Okada, S., and O'Brien, J.S. (1969) Tay-Sachs disease: generalized absence of a beta-D-N-acetylhexosaminidase component. Science, 165, 698-700.
3. Colzelmann, E., and Sandhoff, K. (1978) AB variant of infantile GM2 gangliosidosis: deficiency of a factor necessary for stimulation of hexosaminidase A-catalyzed degradation of ganglioside GM2 and glycolipid GA2. Proc. Natl. Acad. Sci. USA, 75, 3979-3983.
4. Kolodny, E.H., Brady, R.O., and Volk, B.W. (1969) Demonstration of an alteration of ganglioside metabolism in Tay-Sachs disease. Biochem. Biophys. Res. Commun., 37, 526-531.
5. Sandhoff, K. (1969) Variation of beta-N-acetylhexosaminidase-pattern in Tay-Sachs disease. FEBS Lett., 4, 351-354.
6. Robinson, D., and Stirling, J. (1968) N-Acetyl-beta-glucosaminidases in human spleen. Biochem. J., 107, 321-327.
7. Beutler, E., and Kuhl, W. (1975) Subunit structure of human hexosaminidase verified: interconvertibility of hexosaminidase isozymes. Nature (London), 258, 262-264.
8. Srivastava, S.K., Wiktorowicz, J.E., and Awasthi, Y.C. (1976) Interrelationship of hexosaminidases A and B: confirmation of the common and the unique subunit theory. Proc. Natl. Acad. Sci. USA, 73, 2833-2837.
9. Johnson, W.G. (1981) The clinical spectrum of hexosaminidase deficiency disease. Neurology, 31, 1453-1456.
10. Sango, K., Yamanaka, S., Hoffmann, A., Okuda, Y., Grinberg, A., Westphal, H., McDonald, M.P., Crawley, J.N., Sandhoff, K., Suzuki, K., and Proia, R.L. (1995) Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat. Genet., 11, 170-176.
11. Haberland, C., Brunngrager, E., Witting, L., and Brown, B. (1973) The white matter in GM2 gangliosidosis. A comparative histopathological and biochemical study. Acta Neuropathol., 24, 43-55.
12. Puri, V., Watanabe, R., Dominguez, M., Sun, X., Wheatley, C.L., Marks, D.L., and Pagano, R.E. (1999) Cholesterol modulatesmembrane traffic along the endocytic pathway in sphingolipid-storage diseases. Nat. Cell Biol., 1, 386-388.
13. Settembre, C., Fraldi, A., Jahreiss, L., Spampanato, C., Venturi, C., Medina, D., de Pablo, R., Tacchetti, C., Rubinsztein, D.C., and Ballabio, A. (2008) A block of autophagy in lysosomal storage disorders. Hum. Mol. Genet., 17, 119-129.
14. Neuenhofer, S., Conzelmann, E., Schwarzmann, G., Egge, H., and Sandhoff, K. (1986) Occurrence of lysoganglioside lyso-GM2 (II3-Neu5Ac-gangliotriaosylsphingosine) in GM2 gangliosidosis brain. Biol. Chem. Hoppe Seyler, 367, 241-244.
15. Wada, R., Tifft, C.J., and Proia, R.L. (2000) Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc. Natl. Acad. Sci. USA, 97, 10954-10959.
16. Buccoliero, R., Bodennec, J., van Echten-Deckert, G., Sandhoff, K., and Futerman, A. (2004) Phospholipid synthesis is decreased in neuronal tissue in a mouse model of Sandhoff disease. J. Neurochem., 90, 80-88.
17. Baek, R.C., Martin, D.R., Cox, N.R., and Seyfried, T.N. (2009) Comparative analysis of brain lipids in mice, cats and humans with Sandhoff disease. Lipids, 44, 197-205.
18. Cachon-Gonzalez, M.B., Wang, S.Z., Lynch, A., Ziegler, R., Cheng, S.H., and Cox, T.M. (2006) Effective gene therapy in an authentic model of Tay-Sachs related diseases. Proc. Natl. Acad. Sci. USA, 103, 10373-10378.
19. Cachón-González, M.B., Wang, S.Z., McNair, R., Bradley, J., Lunn, D., Ziegler, R., Cheng, S.H., and Cox, T.M. (2012) Gene transfer corrects acute GM2 gangliosidosis-potential therapeutic contribution of perivascular enzyme flow. Mol. Ther., 20, 1489-1500.
20. Bradbury, A.M., Cochran, J.N., McCurdy, V.J., Johnson, A.K., Brunson, B.L., Gray-Edwards, H., Leroy, S.G., Hwang, M., Randle, A.N., Jackson, L.S. et al. (2013) Therapeutic response in feline sandhoff disease despite immunity to intracranial gene therapy. Mol. Ther., 21, 1306-1315.
21. Gallyas, F. (1980) Chemical nature of the first products (nuclei) of the argyrophil staining. Acta Histochem., 67, 145-158.
22. Sargeant, T.J., Wang, S., Bradley, J., Smith, N.J., Raha, A.A., McNair, R., Ziegler, R.J., Cheng, S.H., Cox, T.M., and Cachón-González, M.B. (2011) Adeno-associated virus-mediated expression of b-hexosaminidase prevents neuronal loss in the Sandhoff mouse brain. Hum. Mol. Genet., 20, 4371-4380.
23. Sargeant, T.J., Drage, D.J., Wang, S., Apostolakis, A.A., Cox, T.M., and Cachón-González, M.B. (2012) Characterization of inducible models of Tay-Sachs and related disease. PLoS Genet., 8, e1002943. .
24. Miao, C.H., Nakai, H., Thompson, A.R., Storm, T.A., Chiu, W., Snyder, R.O., and Kay, M.A. (2000) Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction. J. Virol., 74, 3793-3803.
25. Cabrera-Salazar, M.A., Roskelley, E.M., Bu, J., Hodges, B.L., Yew, N., Dodge, J.C., Shihabuddin, L.S., Sohar, I., Sleat, D.E., Scheule, R.K., and Davidson, B.L. (2007) Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile Batten disease. Mol. Ther., 15, 1782-1788.
26. Brooks, A.I., Stein, C.S., Hughes, S.M., Heth, J., McCray, P.M., Sauter, S.L., Johnston, J.C., Cory-Slechta, D.A., Federoff, H.J., and Davidson, B.L. (2002) Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc. Natl. Acad. Sci. USA, 99, 6216-6221.
27. Heldermon, C.D., Qin, E.Y., Ohlemiller, K.K., Herzog, E.D., Brown, J.R., Vogler, C., Hou, W., Orrock, J.L., Crawford, B.E., and Sands, M.S. (2013) Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice. Gene Ther., 20, 913-921.
28. Shibayama-Imazu, T., Okahashi, I., Omata, K., Nakajo, S., Ochiai, H., Nakai, Y., Hama, T., Nakamura, Y., and Nakaya, K. (1993) Cell and tissue distribution and developmental change of neuron specific 14 kDa protein (phosphoneuroprotein 14). Brain Res., 622, 17-25.
29. Jenco, J.M., Rawlingson, A., Daniels, B., and Morris, A.J. (1998) Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by a- and b-synucleins. Biochemistry, 37, 4901-4909.
30. Cole, N.B., Murphy, D.D., Grider, T., Rueter, S., Brasaemle, D., and Nussbaum, R.L. (2002) Lipid droplets binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. J. Biol. Chem., 277, 6344-6352.
31. Golovko, M.Y., Rosenberger, T.A., Faergeman, N.J., Feddersen, S., Cole, N.B., Pribill, I., Berger, J., Nussbaum, R.L., Eric, J., and Murphy, E. (2006) Acyl-CoA synthetase activity links wild-type but not mutant a-synuclein to brain arachidonate metabolism. Biochemistry, 45, 6956-6966.
32. Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R. et al. (2003) Alphasynuclein locus triplication causes Parkinson's disease. Science, 302, 841.
33. Olanow, C.W., and McNaught, K.S. (2006) Ubiquitin-proteasome system and Parkinson's disease. Mov. Disord., 21, 1806-1823.
34. Wong, E., and Cuervo, A.M. (2010) Autophagy gone awry in neurodegenerative diseases. Nat. Neurosci., 13, 805-811.
35. Suzuki, K., Iseki, E., Katsuse, O., Yamaguchi, A., Katsuyama, K., Yamanaka, S., and Kosaka, K. (2003) Neuronal accumulation of a- and b-synucleins in the brain of a GM2 gangliosidosis mouse model. Neuroreport, 14, 551-554.
36. Ashe, K.M., Bangari, D., Li, L., Cabrera-Salazar, M.A., Bercury, S.D., Nietupski, J.B., Cooper, C.G.F., Aerts, J.M.F.G., Lee, E.R., and Copeland, D.P. (2011) Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in amousemodel of Sandhoff disease. PLos ONE, 6, e21758. .
37. Bonifacino, J.S., and Traub, L.M. (2003) Signals for sorting of transmembrane proteins to endosomes and lysosomes. Annu. Rev. Biochem., 72, 395-447.
38. Zhan, S.S., Beyreuther, K., and Schmitt, H.P. (1992) Neuronal ubiquitin and neurofilament expression in different lysosomal storage disorders. Clin. Neuropathol., 11, 251-255.
39. Bifsha, P., Landry, K., Ashmarina, L., Durand, S., Seyrantepe, V., Trudel, S., Quiniou, C., Chemtob, S., Xu, Y., Gravel, R.A., Sladek, R., and Pshezhetsky, A.V. (2007) Altered gene expression in cells from patients with lysosomal storage disorders suggests impairment of the ubiquitin pathway. Cell Death Differ., 14, 511-523.
40. Wu, Y-P., and Proia, R.L. (2004) Deletion of macrophage-inflammatory protein 1a retards neurodegeneration in Sandhoff disease mice. Proc. Natl. Acad. Sci. USA, 101, 8425-8430.
41. Svennerholm, L., Vanier, M-T., and Mansoon, J-E. (1980) Krabbe disease: a galactosylspingosine (psychosine) lipidosis. J. Lipid Res., 21, 53-64.
42. Schall, T.J., Bacon, K., Camp, R.D., Kaspari, J.W., and Goeddel, D.V. (1993) Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemochines attract distinct populations of lymphocytes. J. Exp. Med., 177, 1821-1826.
43. Schall, T.J., Bacon, K., Karen, J.T., and Goeddel, D.V. (1990) Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature, 347, 669-673.
44. Ohno, M., and Komiyama, A. (1993) MHC Class II antigen expression in the demyelinating CNS and PNS of the twitcher mouse. Brain Res., 625, 186-196.
45. Jeyakumar, M., Thomas, R., Elliot-Smith, E., Smith, D.A., van der Spoel, A.C., d'Azzo, A., Perry, V.H., Butters, T.D., Dwek, R.A., and Platt, F.M. (2003) Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain, 126, 974-987.
46. McMahon, E.J., Cook, D.N., Suzuki, K., and Matsushima, G.K. (2001) Absence of Macrophage-infammatory protein-1 a delays central nervous system demyelination in the presence of an intact blood-brain barrier. J. Immunol., 167, 2964-2971.
47. Lane, T.E., Liu, M.T., Chen, B.P., Asensio, V.C., Samawi, R.M., Paoletti, A.D., Campbell, I.L., Kunkel, S.L., Fox, H.S., and Buchmeier, M.J. (2000)A central role forCD4+Tcells andRANTESin virus-induced central nervous system inflammation and demyelination. J. Virol., 74, 1415-1424.
48. Zou, L.P., Pelidou, S.H., Abbas, N., Deretzi, G., Mix, E., Schaltzbeerg, M., Winblad, B., and Zhu, J. (1999) Dynamics of production of MIP-1a, MCP-1 and MIP-2 and potential role of neutralization of these chemokines in the regulation ofimmuneresponses during experimental autoimmune neuritis in Lewis rats. J. Neuroimmunol., 98, 168-175.
49. Huang, J-Q., Trasler, J.M., Igdoura, S., Michaud, J., Hanai, N., and Gravel, R.A. (1997) Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases. Hum. Mol. Genet., 6, 1879-1885.
50. Myerowitz, R., Lawson, D., Mizukami, H., Mi, Y., Tifft, C.J., and Proia, R.L. (2002) Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. Hum. Mol. Genet., 11, 1343-1350.
51. Gulinello, M., Chen, F., and Dobrenis, K. (2008) Early deficits in motor coordination and cognitive dysfunction in a mouse model of the neurodegenerative lysosomal storage disorder, Sandhoff disease. Behav. Brain Res., 193, 315-319.
52. Hu, L., Sun, Y., Villasana, L.E., Paylor, R., Klann, E., and Pautler, R.G. (2009) Early changes in the apparent diffusion coefficient (ADC) in a mouse model of Sandhoff disease occur prior to disease symptoms and behavioural deficits. Magn. Reson. Med., 62, 1175-1184.
53. Haberland, C., and Brunngraber, E.G. (1970) Early infantile neurolipodosis with failure of myelination. A chemical and histopathological study. Arch. Neurol., 23, 481-488.
54. Porter, B.F., Lewis, B.C., Edwards, J.F., Alroy, J., Zeng, B.J., Torres, P.A., Bretzlaff, K.N., and Kolodny, E.H. (2011) Pathology of GM2 gangliosidosis in Jacob sheep. Vet. Pathol., 48, 807-813.
55. Kroll, R.A., Pagel, M.A., Roman-Goldstein, S., Barkovich, A.J., D'Agostino, A.N., and Neuwelt, E.A. (1995) White matter changes associated with felineGM2gangliosidosis (Sandhoff disease): correlation of MR findings with pathologic and ultrastructural abnormalities. Am. J. Neuroradiol., 16, 1219-1226.
56. Kuronen, M., Hermansson, M., Manninen, O., Zech, I., Talvitie, M., Laitinen, T., Gröhn, O., Somerharju, P., Eckhardt, M., Cooper, J.D. et al. (2012) Galactolipid deficiency in the early pathogenesis of neuronal ceroid lipofuscinosis model Cln8mnd: implications to delayed myelination and oligodendrocyte maturation. Neuropath. Appl. Neurobiol., 38, 471-486.
57. Buccinnà, B., Piccinini, M., Prinetti, A., Scandroglio, F., Prioni, S., Valsecchi, M., Votta, B., Grifoni, S., Lupino, E., Ramondetti, C. et al. (2009) Alterations of myelin-specific proteins and sphingolipids characterised the brains of acid sphingomyelinase-deficient mice, an animal model of Niemann-pick disease type A. J. Neurochem., 109, 105-115.
58. Fletcher, J.L., Kondagari, G.S., Wright, A.L., Thomson, P.C., Williamson, P., and Taylor, R.M. (2011) Myelin genes are downregulated in canine fucosidosis. Biochim. Biophys. Acta, 1812, 1418-1426.
59. Duchen, L.W., Eicher, E.M., Jacobs, J.M., Scaravilli, F., and Teixeira, F. (1980) Hereditaryleucodystrophy in the mouse: the new mutant twitcher. Brain, 103, 695-710.
60. Sakai, N., Inui, K., Tatsumi, N., Fukushima, H., Nishigaki, T., Taniike, M., Nishimoto, J., Tsukamoto, H., Yanagihara, I., Ozono, K., and Okada, S. (1996) Molecular cloning and expression of cDNA for murine galactocerebrosidase and mutation analysis of the twitcher mouse, a model of Krabbe's disease. J. Neurochem., 66, 1118-1124.
61. Lacorazza, H.D., and Jendoubi, M. (1995) In situ assessment of beta-hexosaminidase activity. BioTechniques, 19, 434-439.
62. Barthel, L.K., and Raymond, P.A. (2000) In situ hybridization studies of retinal neurons. Methods Enzymol., 316, 579-590.